{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:26:41Z","timestamp":1792175201678,"version":"4.4.0"},"reference-count":65,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/08916934.2025.2551517","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:26:41Z","timestamp":1757154401000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer\/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada"],"prefix":"10.1080","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1745-3263","authenticated-orcid":false,"given":"David J.","family":"Speicher","sequence":"first","affiliation":[{"name":"Department of Pathobiology, University of Guelph","place":["Guelph, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-4425","authenticated-orcid":false,"given":"Jessica","family":"Rose","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-1122","authenticated-orcid":false,"given":"Kevin","family":"McKernan","sequence":"additional","affiliation":[{"name":"Medicinal Genomics","place":["Beverly, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"de Fougerolles A Elbashir SM. Delivery and formulation of engineered nucleic acids. United States Patent and Trademark Office Modernatx Inc; 2021. https:\/\/patents.google.com\/patent\/US10898574B2\/en https:\/\/patentimages.storage.googleapis.com\/29\/f1\/5c\/fda42b8d8dd5ca\/US10898574.pdf"},{"key":"e_1_3_4_3_1","first-page":"o1731","article-title":"Effect of mRNA vaccine manufacturing processes on efficacy and safety still an open question","volume":"378","author":"Guetzkow JA","year":"2023","unstructured":"Guetzkow JA, Levi R. Effect of mRNA vaccine manufacturing processes on efficacy and safety still an open question. BMJ. 2023;378:o1731.","journal-title":"BMJ"},{"key":"e_1_3_4_4_1","unstructured":"Rabe I Buff M Ziegenhals N. In vitro transcription technologies. United States Patent and Trademark Office; 2023. https:\/\/patentimages.storage.googleapis.com\/03\/aa\/75\/b6d7d2995c9653\/US20230183769A1.pdf"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3210481"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102803"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n627"},{"key":"e_1_3_4_8_1","unstructured":"EMEA\/H\/C\/005735\/RR. Rapporteur rolling review critical assessment report: quality aspects. European Medicines Agency; 2020. https:\/\/covidvaccinereactions.com\/ema-pfizer-leak\/"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/b9t7m"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.035"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/mjc97"},{"key":"e_1_3_4_12_1","unstructured":"International Council for Harmonisation (ICH). Q6B: specifications: test procedures and acceptance criteria for biotechnological\/biological products; 1999. Retrieved from https:\/\/database.ich.org\/sites\/default\/files\/Q6B%20Guideline.pdf"},{"key":"e_1_3_4_13_1","unstructured":"Food and Drug Administration. Chemistry manufacturing and control (CMC) information for human gene therapy investigational new drug applications (INDs). U.S. Department of Health and Human Services; 2020. from https:\/\/www.fda.gov\/media\/113760\/download."},{"key":"e_1_3_4_14_1","unstructured":"Public Health Agency of Canada. National Vaccine Catalogue: Vaccine lot. 2024. Retrieved from https:\/\/nvc-cnv.canada.ca\/en\/vaccine-lots"},{"key":"e_1_3_4_15_1","unstructured":"VAERS Team.Vaccine Adverse Event Reporting System (VAERS) Standard Operating Procedures for COVID-19 (as of 29 January 2021) Retrieved from https:\/\/www.cdc.gov\/vaccinesafety\/pdf\/VAERS-v2-SOP.pdf"},{"key":"e_1_3_4_16_1","unstructured":"Port Hedland. Australia - special council meeting agenda - 11 October 2024 attachments. Council of the Town of Port Hedland; 2024. Retrieved from https:\/\/www.porthedland.wa.gov.au\/council-meetings\/special-council-meetings\/special-council-meeting-11-october-2024\/247\/documents\/attachments_scm_11102024.pdf"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4716"},{"key":"e_1_3_4_18_1","unstructured":"New England Biolabs. NEBioCalculator; 2023."},{"key":"e_1_3_4_19_1","unstructured":"R Development Core Team. R: The R project for statistical computing. R Foundation for Statistical Computing; 2010. Retrieved from http:\/\/www.R-project.org"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.12.005"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2024.115577"},{"key":"e_1_3_4_23_1","unstructured":"VAERS Team. VAERS data users guide; 2020. Retrieved from https:\/\/vaers.hhs.gov\/docs\/VAERSDataUseGuide_November2020.pdf"},{"key":"e_1_3_4_24_1","unstructured":"South Carolina Senate. SC Senate Hearing - USC Professor Dr. Phillip Buckhaults; 2023."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/mps7030041"},{"key":"e_1_3_4_26_1","unstructured":"K\u00e4mmerer U Schulz V Steger K. BioNTech RNA-Based COVID-19 Injections Contain Large Amounts Of Residual DNA Including An SV40 Promoter\/Enhancer Sequence. Science Public Health Policy and the Law 5:1-22. Retrieved from https:\/\/publichealthpolicyjournal.com\/biontech-rna-based-covid-19-injections-contain-large-amounts-of-residual-dna-including-an-sv40-promoter-enhancer-sequence\/"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.64336\/001c.127890"},{"key":"e_1_3_4_28_1","unstructured":"European Medicines Agency. EMA\/896245\/2022: Assessment report for Spikevax. 2022 Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/spikevax-previously-covid-19-vaccine-moderna-h-c-005791-ii-0075-g-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_4_29_1","unstructured":"U.S. Food and Drug Administration. Emergency use authorization (EUA) for an unapproved product review memorandum. 2021. Retrieved from https:\/\/www.fda.gov\/media\/153947\/download"},{"key":"e_1_3_4_30_1","unstructured":"Food and Drug Administration. Letter of authorization; 2023. Retrieved from https:\/\/www.fda.gov\/media\/150386\/download"},{"key":"e_1_3_4_31_1","unstructured":"U.S. Department of Health and Human Services.Inspection of Injectable Products for Visible Particulates Guidance for Industry 2021. Retrieved from https:\/\/www.fda.gov\/media\/154868\/download"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26926-0"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06235-0"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-765X.2009.02788.x"},{"key":"e_1_3_4_35_1","unstructured":"EMEA\/H\/C\/005735\/0000. Comirnaty European Public Assessment Report (EPAR). 2021. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/comirnaty-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_4_36_1","unstructured":"European Medicines Agency. EMA\/CHMP\/50784\/2022: type IB variation report; 2022. Retrieved from https:\/\/postvac.org\/wp-content\/uploads\/wpforo\/attachments\/3025\/1252-Type-IB-variation-report.pdf"},{"key":"e_1_3_4_37_1","first-page":"118","article-title":"Pfizer\/BioNTech\u2019s COVID-19 modRNA vaccines: dangerous genetic mechanism of action released before sufficient preclinical testing","volume":"29","author":"Oldfield PR","year":"2024","unstructured":"Oldfield PR, Gutschi LM, McCullough PA, et al. Pfizer\/BioNTech\u2019s COVID-19 modRNA vaccines: dangerous genetic mechanism of action released before sufficient preclinical testing. J Am Phys Surgeons. 2024;29:118\u2013126.","journal-title":"J Am Phys Surgeons"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.006"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060798"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/nt8jh"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06800-3"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.131427"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.18.25322379"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021404"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2021-0280"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjac058"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13998"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300924"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33862-0"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01148-x"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275408"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0761"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70680-4"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.222"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127022"},{"key":"e_1_3_4_57_1","unstructured":"World Health Organization. Annex 3: requirements for the use of animal cell cultures as substrates for the manufacture of biologic medicinal products and the characterization of cell banks. Replacement of Annex 1 of WHO Technical Report Series No. 878; 2013. Retrieved from https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/documents\/trs_978_annex_3.pdf"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.02.015"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03166-5"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.12.029"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.193"},{"key":"e_1_3_4_62_1","unstructured":"Prime Minister\u2019s Office of Japan. COVID-19 vaccines; 2024. https:\/\/japan.kantei.go.jp\/ongoingtopics\/vaccine.htm"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.11.025"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2016.03.002"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2024.200293"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10769"}],"container-title":["Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08916934.2025.2551517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:00:16Z","timestamp":1766052016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08916934.2025.2551517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/08916934.2025.2551517"],"URL":"https:\/\/doi.org\/10.1080\/08916934.2025.2551517","relation":{},"ISSN":["0891-6934","1607-842X"],"issn-type":[{"value":"0891-6934","type":"print"},{"value":"1607-842X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iaut20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iaut20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2551517"}}